BiotechTube
Allyx Therapeutics

Allyx Therapeutics

New Haven, United States· Est.
allyxthera.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

Allyx Therapeutics is a private, Series A-stage biotech based in New Haven, CT, pioneering a synapse-protection approach for neurodegenerative diseases. Its lead asset, ALX-001, is a first-in-class, oral mGluR5 modulator that has completed Phase 1a/b studies, demonstrating safety, full brain receptor occupancy, and progression into patient trials for both Alzheimer's and Parkinson's disease. The company is backed by venture capital and significant non-dilutive NIH funding, positioning it to advance into Phase 2 clinical development.

Alzheimer's DiseaseParkinson's DiseaseNeurodegenerative Diseases

Technology Platform

First-in-class oral negative allosteric modulators of the metabotropic glutamate receptor 5 (mGluR5) designed to protect synapses from toxic signaling in neurodegenerative diseases.

Funding History

1
Total raised:$12M
Seed$12M

Opportunities

The massive, unmet need for safe, effective, and convenient oral therapies in Alzheimer's and Parkinson's disease presents a multi-billion dollar market opportunity.
Positive clinical data could position ALX-001 as a complementary or superior therapy to current injectable biologics.
The company's strong academic roots and NIH grant support provide validation and extend its financial runway.

Risk Factors

The novel mGluR5 mechanism may fail to show clinical efficacy in ongoing patient trials.
The company faces intense competition from larger players with substantial resources.
As a private, clinical-stage biotech, Allyx remains dependent on successful future fundraising to advance its programs to later stages.

Competitive Landscape

Allyx operates in the highly competitive neurodegenerative disease space, competing with large pharma (e.g., Biogen, Eli Lilly, Roche) developing amyloid, tau, and other novel-target therapies. Its primary differentiation is the first-in-class, oral synapse-protection approach via mGluR5, a niche with limited clinical-stage competition compared to more crowded mechanisms.

More companies in Small Molecule Drugs →More companies in United States →